Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pyxis Oncology (PYXS) EBITDA: 2024-2025

Historic EBITDA for Pyxis Oncology (PYXS) over the last 2 years, with Sep 2025 value amounting to -$21.9 million.

  • Pyxis Oncology's EBITDA fell 5.68% to -$21.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$97.4 million, marking a year-over-year change of. This contributed to the annual value of -$77.2 million for FY2024, which is 4.74% down from last year.
  • According to the latest figures from Q3 2025, Pyxis Oncology's EBITDA is -$21.9 million, which was down 19.13% from -$18.4 million recorded in Q2 2025.
  • Pyxis Oncology's EBITDA's 5-year high stood at -$3.4 million during Q1 2024, with a 5-year trough of -$35.8 million in Q4 2024.
  • For the 2-year period, Pyxis Oncology's EBITDA averaged around -$19.8 million, with its median value being -$20.8 million (2024).
  • Data for Pyxis Oncology's EBITDA shows a maximum YoY tumbled of 529.74% (in 2025) over the last 5 years.
  • Quarterly analysis of 2 years shows Pyxis Oncology's EBITDA stood at -$35.8 million in 2024, then declined by 5.68% to -$21.9 million in 2025.
  • Its EBITDA was -$21.9 million in Q3 2025, compared to -$18.4 million in Q2 2025 and -$21.3 million in Q1 2025.